A Review on Currently Available Potential Therapeutic Options for COVID-19

References

• Sun PLX, Xu C, Sun W, Pan B, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548–551. doi:10.1002/jmv.2572232096567
   PubMed Web of Science ®Google Scholar
• Qun LMM, Xuhua G, Peng W, Xiaoye Wang MPH. Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia. N Engl J Med. 2020.
   Web of Science ®Google Scholar
• Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Nat Sci Rev. 2020;7(6):1012–1023. doi:10.1093/nsr/nwaa036
   PubMed Web of Science ®Google Scholar
• Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–1033. doi:10.3390/v406101122816037
   PubMed Web of Science ®Google Scholar
• Cai G. Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov. MedRxiv. 2020.
   Google Scholar
• Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020;80(6):e14–e18. doi:10.1016/j.jinf.2020.03.005
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451–1454. doi:10.1038/s41418-020-0530-332205856
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X32085846
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi:10.1172/JCI13724432217835
   PubMed Web of Science ®Google Scholar
• Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-531986264
   PubMed Web of Science ®Google Scholar
• Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020;53(3):371–372. doi:10.1016/j.jmii.2020.02.01132147409
   PubMedGoogle Scholar
• Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282(1821):20143085.26702035
   PubMed Web of Science ®Google Scholar
• Nickbakhsh S, Mair C, Matthews L, et al. Virus-virus interactions impact the population dynamics of influenza and the common cold. Proc Natl Acad Sci U S A. 2019;116(52):27142–27150. doi:10.1073/pnas.1911083116
   Web of Science ®Google Scholar
• Uhlen M, Karlsson MJ, Zhong W, et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Science. 2019;366(6472):6472. doi:10.1126/science.aax9198
   Web of Science ®Google Scholar
• Bhadra S, Jiang YS, Kumar MR, Johnson RF, Hensley LE, Ellington AD. Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV). PloS One. 2015;10(4):e0123126. doi:10.1371/journal.pone.012312625856093
   PubMed Web of Science ®Google Scholar
• Chan JF, Choi GK, Tsang AK, et al. Development and evaluation of novel real-time reverse transcription-PCR assays with locked nucleic acid probes targeting leader sequences of human-pathogenic coronaviruses. J Clin Microbiol. 2015;53(8):2722–2726. doi:10.1128/JCM.01224-1526019210
   PubMed Web of Science ®Google Scholar
• Huang P, Wang H, Cao Z, et al. A Rapid and Specific Assay for the Detection of MERS-CoV. Front Microbiol. 2018;9:1101. doi:10.3389/fmicb.2018.0110129896174
   PubMed Web of Science ®Google Scholar
• Lee SH, Baek YH, Kim YH, Choi YK, Song MS, Ahn JY. One-pot reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) for Detecting MERS-CoV. Front Microbiol. 2016;7:2166.28119682
   PubMed Web of Science ®Google Scholar
• Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa344
   Web of Science ®Google Scholar
• Myhrvold C, Freije CA, Gootenberg JS, et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science. 2018;360(6387):444–448. doi:10.1126/science.aas883629700266
   PubMed Web of Science ®Google Scholar
• Wang J, Du G. COVID-19 may transmit through aerosol. Ir J Med Sci. 2020;1–2.
   Web of Science ®Google Scholar
• Kanne JP. Chest CT Findings in 2019 Novel Coronavirus (2019-Ncov) Infections from Wuhan, China: Key Points for the Radiologist. Radiological Society of North America; 2020.
   Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Deng S-Q, Peng H-J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med. 2020;9(2):575. doi:10.3390/jcm9020575
   PubMed Web of Science ®Google Scholar
• Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. J Med Virol. 2020.
   Web of Science ®Google Scholar
• Tobaiqy M, Qashqary M, Al-Dahery S, et al. Therapeutic management of patients with COVID-19: a systematic review. Infect Prevent Pract. 2020;2(3):100061.
   PubMedGoogle Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-732007143
   PubMed Web of Science ®Google Scholar
• Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020. doi:10.1016/j.jmii.2020.05.013
   Google Scholar
• Lai -C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi:10.1016/j.ijantimicag.2020.10592432081636
   PubMed Web of Science ®Google Scholar
• Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71. doi:10.5582/bst.2020.0102031996494
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019 nCoV) in vitro [published online February 4, 2020]. Cell Res. 2020;30;269.32020029
   PubMed Web of Science ®Google Scholar
• De Savi C, Hughes DL, Kvaerno L. Quest for a COVID-19 Cure by repurposing small-molecule drugs: mechanism of action, clinical development, synthesis at scale, and outlook for supply. Org Process Res Dev. 2020;24(6):940–976. doi:10.1021/acs.oprd.0c00233
   Web of Science ®Google Scholar
• Liu C, Zhou Q, Li Y, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Sci. 2020;6(3):315–331. doi:10.1021/acscentsci.0c00272
   PubMed Web of Science ®Google Scholar
• Sandra S, Bart P, Vasilios P, Christos P, Mihael P. Direct ACE2- Spike RBD Binding Disruption with Small Molecules: A Strategy for COVID-19 Treatment. 2020.
   Google Scholar
• Sachin P, Jeremy H, Pedro JB, et al. Drug repurposing for covid-19: discovery of potential small-molecule inhibitors of spike Protein-ACE2 receptor interaction through virtual screening and consensus scoring. 2020.
   Google Scholar
• Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913.e907. doi:10.1016/j.cell.2020.04.00432333836
   PubMed Web of Science ®Google Scholar
• Leneva IA, Russell RJ, Boriskin YS, Hay AJ. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009;81(2):132–140. doi:10.1016/j.antiviral.2008.10.00919028526
   PubMed Web of Science ®Google Scholar
• Blaising J, Lévy PL, Polyak SJ, Stanifer M, Boulant S, Pécheur EI. Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antiviral Res. 2013;100(1):215–219. doi:10.1016/j.antiviral.2013.08.00823981392
   PubMed Web of Science ®Google Scholar
• Blaising J, Polyak SJ, Pécheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84–94. doi:10.1016/j.antiviral.2014.04.00624769245
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020.
   Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–613. doi:10.1016/j.jinf.2020.03.03732283152
   PubMed Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934. doi:10.1001/jamainternmed.2020.0994
   PubMed Web of Science ®Google Scholar
• Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020.
   PubMedGoogle Scholar
• Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi:10.1016/j.ebiom.2020.10276332361250
   PubMed Web of Science ®Google Scholar
• McGonagle D, Sharif K, O’Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537. doi:10.1016/j.autrev.2020.10253732251717
   PubMed Web of Science ®Google Scholar
• Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discovery. 2020;6(1):31. doi:10.1038/s41421-020-0168-932377375
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020.
   Web of Science ®Google Scholar
• Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53(3):368–370. doi:10.1016/j.jmii.2020.03.00532205092
   PubMedGoogle Scholar
• Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Translat Res. 2020;220:1–13. doi:10.1016/j.trsl.2020.04.007
   PubMed Web of Science ®Google Scholar
• Ingraham NE, Lotfi-Emran S, Thielen BK, et al. Immunomodulation in COVID-19. Lancet Respir Med. 2020;8(6):544–546. doi:10.1016/S2213-2600(20)30226-532380023
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China. Clin immunol. 2020;214:108393. doi:10.1016/j.clim.2020.10839332222466
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care. medRxiv. 2020.
   Google Scholar
• Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e331. e325-e331. doi:10.1016/S2665-9913(20)30127-232501454
   PubMedGoogle Scholar
• Safavi F, Nath A. Silencing of immune activation with methotrexate in patients with COVID-19. J Neurol Sci. 2020;116942. doi:10.1016/j.jns.2020.11694232471659
   PubMed Web of Science ®Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475. doi:10.1016/S0140-6736(20)30317-232043983
   PubMed Web of Science ®Google Scholar
• Haberman R, Axelrad J, Chen A, et al. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. N Engl J Med. 2020;383(1):85–88. doi:10.1056/NEJMc200956732348641
   PubMed Web of Science ®Google Scholar
• Luo W, Li YX, Jiang LJ, Chen Q, Wang T, Ye DW. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends Pharmacol Sci. 2020. doi:10.1016/j.tips.2020.06.007
   Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi:10.1038/nrd.2017.20129104284
   PubMed Web of Science ®Google Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31. doi:10.1016/S0140-6736(20)30304-432032529
   PubMed Web of Science ®Google Scholar
• Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi:10.5582/bst.2020.0104732074550
   PubMed Web of Science ®Google Scholar
• Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30(4):297–308. doi:10.1016/j.ijantimicag.2007.05.01517629679
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69. doi:10.1186/1743-422X-2-6916115318
   PubMed Web of Science ®Google Scholar
• Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323(1):264–268. doi:10.1016/j.bbrc.2004.08.08515351731
   PubMed Web of Science ®Google Scholar
• Kono M, Tatsumi K, Imai AM, Saito K, Kuriyama T, Shirasawa H. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res. 2008;77(2):150–152. doi:10.1016/j.antiviral.2007.10.01118055026
   PubMed Web of Science ®Google Scholar
• Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60. doi:10.5582/ddt.2020.0101232147628
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents;2020 105949. doi:10.1016/j.ijantimicag.2020.10594932205204
   PubMed Web of Science ®Google Scholar
• Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55(5):105938. doi:10.1016/j.ijantimicag.2020.10593832171740
   PubMed Web of Science ®Google Scholar
• Page CP. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol. 2014;165(3):152–164. doi:10.1159/00036880025532037
   PubMed Web of Science ®Google Scholar
• Raker VK, Becker C, Steinbrink K. The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases. Front Immunol. 2016;7:123. doi:10.3389/fimmu.2016.0012327065076
   PubMed Web of Science ®Google Scholar
• Azevedo MF, Faucz FR, Bimpaki E, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev. 2014;35(2):195–233. doi:10.1210/er.2013-105324311737
   PubMed Web of Science ®Google Scholar
• Li H, Zuo J, Tang W. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol. 2018;9:1048. doi:10.3389/fphar.2018.0104830386231
   PubMed Web of Science ®Google Scholar
• Schafer PH, Truzzi F, Parton A, et al. Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cell Signal. 2016;28(7):753–763. doi:10.1016/j.cellsig.2016.01.00726806620
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590. doi:10.1016/j.bcp.2012.01.00122257911
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–855. doi:10.1111/j.1476-5381.2009.00559.x20050849
   PubMed Web of Science ®Google Scholar
• Crowe CR, Chen K, Pociask DA, et al. Critical role of IL-17RA in immunopathology of influenza infection. J Immunol. 2009;183(8):5301–5310. doi:10.4049/jimmunol.090099519783685
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Fabbrocini G. May IL-17 have a role in COVID-19 infection? Med Hypotheses. 2020;140:109749. doi:10.1016/j.mehy.2020.10974932339777
   PubMed Web of Science ®Google Scholar
• Méhats C, Franco-Montoya ML, Boucherat O, et al. Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats. PloS One. 2008;3(10):e3445. doi:10.1371/journal.pone.000344518941502
   PubMed Web of Science ®Google Scholar
• Sisson TH, Christensen PJ, Muraki Y, et al. Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury. Physiol Rep. 2018;6(12):e13753. doi:10.14814/phy2.1375329952109
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Karampela I, Mantzoros CS. Commentary: phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metabolism. 2020;109:154282. doi:10.1016/j.metabol.2020.15428232497535
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Pizzatti L, Sanna S, Atzori L, Rongioletti F. CID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management. J Eur Acad Dermatol Venereol. 2020. doi:10.1111/jdv.16625
   Web of Science ®Google Scholar
• Olisova OY, Anpilogova EM, Svistunova DA. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient. Dermatol Ther. 2020;e13668.32449265
   PubMed Web of Science ®Google Scholar
• Frohman EM, Villemarette-Pittman NR, Cruz RA, et al. Part II. High-dose methotrexate with leucovorin rescue for severe COVID-19: an immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’ attack. J Neurol Sci. 2020;116935.32534807
   PubMed Web of Science ®Google Scholar
• Cribbs AP, Kennedy A, Penn H, et al. Methotrexate Restores Regulatory T Cell Function Through Demethylation of the FoxP3 Upstream Enhancer in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2015;67(5):1182–1192. doi:10.1002/art.3903125604080
   PubMed Web of Science ®Google Scholar
• Kuroiwa Y, Takakusagi Y, Kusayanagi T, et al. Identification and characterization of the direct interaction between methotrexate (MTX) and high-mobility group box 1 (HMGB1) protein. PloS One. 2013;8(5):e63073. doi:10.1371/journal.pone.006307323658798
   PubMed Web of Science ®Google Scholar
• Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology. 2003;42(10):1189–1196. doi:10.1093/rheumatology/keg32312777636
   PubMed Web of Science ®Google Scholar
• Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–443. doi:10.1016/j.jmii.2020.03.03432307245
   PubMedGoogle Scholar
• Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme Inhibitors in Hypertension: to Use or Not to Use? J Am Coll Cardiol. 2018;71(13):1474–1482. doi:10.1016/j.jacc.2018.01.05829598869
   PubMed Web of Science ®Google Scholar
• Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus Disease 2019 (COVID-19): do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? J Am Heart Assoc. 2020;9(7):e016509. doi:10.1161/JAHA.120.01650932233753
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Krüger N, Mueller MA, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. Biorxiv. 2020.
   Google Scholar
• Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610. doi:10.1161/CIRCULATIONAHA.104.51046115897343
   PubMed Web of Science ®Google Scholar
• Sommerstein R, Gräni C, Cullen MR, Basu S. Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19. BMJ. 2020;368:m810.32111649
   PubMed Web of Science ®Google Scholar
• Phadke M, Saunik S. COVID-19 treatment by repurposing drugs until the vaccine is in sight. Drug Dev Res. 2020. doi:10.1002/ddr.21666
   PubMed Web of Science ®Google Scholar
• Phadke M, Saunik S. Rapid response: use of angiotensin receptor blockers such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections—Novel mode of treatment. Response to the emerging novel coronavirus outbreak. BMJ. 2020;368:m406. doi:10.1136/bmj.l696832005675
   PubMed Web of Science ®Google Scholar
• Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Research. 2020;9:72. doi:10.12688/f1000research.22211.232117569
   PubMedGoogle Scholar
• Gao H, Dai W, Zhao L, Min J, Wang F. The Role of Zinc and Zinc Homeostasis in Macrophage Function. J Immunol Res. 2018;2018:6872621. doi:10.1155/2018/687262130622979
   PubMed Web of Science ®Google Scholar
• Rentsch CT, Kidwai-Khan F, Tate JP, et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54–75 Years. medRxiv. 2020.
   Google Scholar
• Bean D, Kraljevic Z, Searle T, et al. ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS- COVID19 infection in a multi-site UK acute Hospital Trust. medRxiv. 2020.
   Google Scholar
• Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020;201(11):1380–1388. doi:10.1164/rccm.202002-0445OC32275452
   PubMed Web of Science ®Google Scholar
• Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv. 2020.
   Google Scholar
• Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760. doi:10.1080/22221751.2020.174620032228222
   PubMed Web of Science ®Google Scholar
• Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R. Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia, Italy. medRxiv. 2020.
   Google Scholar
• Leyssen P, Balzarini J, De Clercq E, Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol. 2005;79(3):1943–1947. doi:10.1128/JVI.79.3.1943-1947.200515650220
   PubMed Web of Science ®Google Scholar
• De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chem Asian J. 2019;14(22):3962–3968. doi:10.1002/asia.20190084131389664
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: an Open-Label Control Study. Engineering. 2020.
   Web of Science ®Google Scholar
• Ahn DG, Shin HJ, Kim MH, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313–324. doi:10.4014/jmb.2003.0301132238757
   PubMed Web of Science ®Google Scholar
• Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–347. doi:10.1038/nrd.2015.3726868298
   PubMed Web of Science ®Google Scholar
• Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69–75. doi:10.1016/j.jcv.2004.03.00315288617
   PubMed Web of Science ®Google Scholar
• Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326(4):905–908. doi:10.1016/j.bbrc.2004.11.12815607755
   PubMed Web of Science ®Google Scholar
• Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. J Med Virol. 2020;92(7):740–746. doi:10.1002/jmv.2579832227493
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int j Infect Dis. 2014;20:42–46. doi:10.1016/j.ijid.2013.12.00324406736
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):396. doi:10.1126/scitranslmed.aal3653
   Web of Science ®Google Scholar
• McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859. doi:10.1016/j.phrs.2020.10485932360480
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018;9(2):2. doi:10.1128/mBio.00221-18
   Web of Science ®Google Scholar
• Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12(4):4. doi:10.3390/v12040372
   Web of Science ®Google Scholar
• Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med j. 2003;9(6):399–406.14660806
   PubMedGoogle Scholar
• Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256. doi:10.1136/thorax.2003.01265814985565
   PubMed Web of Science ®Google Scholar
• Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):455–459. doi:10.3851/IMP300226492219
   PubMed Web of Science ®Google Scholar
• Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704. doi:10.1016/S0140-6736(20)31042-432401715
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004;318(3):719–725. doi:10.1016/j.bbrc.2004.04.08315144898
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Matsuyama S, Hoshino T, Yamamoto N. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. bioRxiv. 2020.
   Google Scholar
• Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa200128232187464
   PubMed Web of Science ®Google Scholar
• Meng Z, Wang T, Li C, et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv. 2020.
   Google Scholar
• Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–386. doi:10.1038/nri160415864272
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Vicenzi E, Bellomi F, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther. 2004;9(6):1003–1011.15651759
   PubMed Web of Science ®Google Scholar
• Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293–294. doi:10.1016/S0140-6736(03)13973-612892961
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020;11:1061. doi:10.3389/fimmu.2020.0106132574262
   PubMed Web of Science ®Google Scholar
• World Health O. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (‎‎‎‎‎2019-Ncov)‎‎‎‎‎ Infection is Suspected: Interim Guidance, 28 January 2020. Geneva: World Health Organization; 2020:2020.
   Google Scholar
• Nodarse-Cuní HL-SP. Cuban interferon alpha-2b. Thirty years as an effective and safe drug. Biotecnol Apl. 2020;34(1):1211–1217.
   Google Scholar
• Pereda R, Gonzalez D, Rivero H, et al. Therapeutic effectiveness of interferon-alpha2b against COVID-19: the Cuban experience. medRxiv. 2020.
   Google Scholar
• Reiter RJ, Ma Q, Sharma R. Treatment of Ebola and other infectious diseases: melatonin “goes viral”. Melatonin Res. 2020;3(1):43–57. doi:10.32794/mr11250047
   Google Scholar
• Zhang R, Wang X, Ni L, et al. COVID-19: melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583.32217117
   PubMed Web of Science ®Google Scholar
• Zarezadeh M, Khorshidi M, Emami M, et al. Melatonin supplementation and pro-inflammatory mediators: a systematic review and meta-analysis of clinical trials. Eur J Nutr. 2019. doi:10.1007/s00394-019-02123-0
   Web of Science ®Google Scholar
• Zhang R, Wang X, Ni L, et al. COVID-19: melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583. doi:10.1016/j.lfs.2020.11758332217117
   PubMed Web of Science ®Google Scholar
• Marovich M, Mascola JR, Cohen MS. Monoclonal Antibodies for Prevention and Treatment of COVID-19. Jama. 2020. doi:10.1001/jama.2020.10245
   Web of Science ®Google Scholar
• Prabakaran P, Zhu Z, Xiao X, et al. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther. 2009;9(3):355–368. doi:10.1517/1471259090276375519216624
   PubMed Web of Science ®Google Scholar
• Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A. 2004;101(8):2536–2541. doi:10.1073/pnas.030714010114983044
   PubMed Web of Science ®Google Scholar
• Cutino-Moguel MT, Eades C, Rezvani K, Armstrong-James D. Immunotherapy for infectious diseases in haematological immunocompromise. Br J Haematol. 2017;177(3):348–356. doi:10.1111/bjh.1459528369798
   PubMed Web of Science ®Google Scholar
• van den Brink EN, Ter Meulen J, Cox F, et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol. 2005;79(3):1635–1644. doi:10.1128/JVI.79.3.1635-1644.200515650189
   PubMed Web of Science ®Google Scholar
• Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem. 2004;279(5):3197–3201. doi:10.1074/jbc.C30052020014670965
   PubMed Web of Science ®Google Scholar
• Ju B, Zhang Q, Ge X, et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv. 2020.
   Google Scholar
• Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–295. doi:10.1038/s41586-020-2349-y32422645
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251. doi:10.1038/s41467-020-16256-y32366817
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang F, Shen C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020;368(6496):1274–1278. doi:10.1126/science.abc224132404477
   PubMed Web of Science ®Google Scholar
• Hamilton JA. GM-CSF-Dependent Inflammatory Pathways. Front Immunol. 2019;10:2055. doi:10.3389/fimmu.2019.0205531552022
   PubMed Web of Science ®Google Scholar
• Hamilton JA. GM-CSF in inflammation and autoimmunity. Trends Immunol. 2002;23(8):403–408. doi:10.1016/S1471-4906(02)02260-312133803
   PubMed Web of Science ®Google Scholar
• De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020. doi:10.1016/S2665-9913(20)30170-3
   Google Scholar
• Temesgen Z, Assi M, Vergidis P, et al. First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia. medRxiv. 2020.
   Google Scholar
• Megan M, Jared N, Jacquelyn H, et al. Case Report: use of Lenzilumab and Tocilizumab for the Treatment of Coronavirus Disease 2019. Immunotherapy;2020.
   Web of Science ®Google Scholar
• Picchianti Diamanti A, Rosado MM, Pioli C, Sesti G, Laganà B. Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: the Fragile Balance between Infections and Autoimmunity. Int J Mol Sci. 2020;21(9):3330. doi:10.3390/ijms21093330
   Web of Science ®Google Scholar
• Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848. doi:10.1007/s00134-020-05991-x32125452
   PubMed Web of Science ®Google Scholar
• Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50(4):1007–1023. doi:10.1016/j.immuni.2019.03.02630995492
   PubMed Web of Science ®Google Scholar
• Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395–412. doi:10.1038/nrd.2018.4529725131
   PubMed Web of Science ®Google Scholar
• Kato S, Kurzrock R. Repurposing Interleukin-6 Inhibitors to Combat COVID-19. J Immunother Precision Oncol. 2020;3(2):52–55.
   Google Scholar
• Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2(5):247–256. doi:10.1177/1759720X1037837222870451
   PubMedGoogle Scholar
• van Rhee F, Casper C, Voorhees PM, et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol. 2020;7(3):e209–e217. e209-e217. doi:10.1016/S2352-3026(19)30257-132027862
   PubMed Web of Science ®Google Scholar
• Van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti–interleukin-6 monoclonal antibody, for Castleman’s disease. J clin oncol. 2010;28(23):3701–3708. doi:10.1200/JCO.2009.27.237720625121
   PubMed Web of Science ®Google Scholar
• Ascierto P, Fox B, Urba W. SITC statement on anti-IL-6/IL-6R for COVID-19. Society Immunother Cancer. 2020.
   Google Scholar
• Calabrese C, Rajendram P, Sacha G, Calabrese L. Practical aspects of targeting IL-6 in COVID-19 disease. Cleve Clin J Med. 2020. doi:10.3949/ccjm.87a.ccc018
   Google Scholar
• Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID‐19: A single center experience. J Med Virol. 2020;92(7):814–818. doi:10.1002/jmv.2580132253759
   PubMed Web of Science ®Google Scholar
• Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1):1–5. doi:10.1186/s12967-020-02339-331900168
   PubMed Web of Science ®Google Scholar
• Kimmig LM, Wu D, Gold M, et al. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. medRxiv. 2020.
   PubMedGoogle Scholar
• Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–27. doi:10.1111/imr.1262129247995
   PubMed Web of Science ®Google Scholar
• Schmitz N, Kurrer M, Bachmann MF, Kopf M. Interleukin-1 Is Responsible for Acute Lung Immunopathology but Increases Survival of Respiratory Influenza Virus Infection. J Virol. 2005;79(10):6441–6448. doi:10.1128/JVI.79.10.6441-6448.200515858027
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–652. doi:10.1038/nrd380022850787
   PubMed Web of Science ®Google Scholar
• La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–2477. doi:10.1182/blood.201889461830992265
   PubMed Web of Science ®Google Scholar
• van der Ven AJ, Netea MG, van der Meer JW, de Mast Q. Ebola Virus Disease has Features of Hemophagocytic Lymphohistiocytosis Syndrome. Fron Med. 2015;2:4. doi:10.3389/fmed.2015.00004
   Web of Science ®Google Scholar
• Filocamo G, Mangioni D, Tagliabue P, et al. Use of anakinra in severe COVID-19: a case report. Int j Infect Dis. 2020;96:607–609. doi:10.1016/j.ijid.2020.05.02632437934
   PubMed Web of Science ®Google Scholar
• Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–e400. e393-e400. doi:10.1016/S2665-9913(20)30164-8
   PubMedGoogle Scholar
• Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3(9):745–756. doi:10.1038/nri118412949498
   PubMed Web of Science ®Google Scholar
• Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32. doi:10.1128/MMBR.05015-1122390970
   PubMed Web of Science ®Google Scholar
• Wu P, Hao X, Lau EHY, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveillance. 2020;25:3.
   Google Scholar
• Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919–922. doi:10.1093/jac/dki34616183666
   PubMed Web of Science ®Google Scholar
• Arabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus. 2015;4(1):709. doi:10.1186/s40064-015-1490-926618098
   PubMedGoogle Scholar
• Zhou B, Zhong N, Guan Y. Treatment with Convalescent Plasma for Influenza A (H5N1) Infection. N Eng J Med. 2007;357(14):1450–1451. doi:10.1056/NEJMc070359
   PubMed Web of Science ®Google Scholar
• Tanne JH. Covid-19: FDA Approves Use of Convalescent Plasma to Treat Critically Ill Patients. British Medical Journal Publishing Group; 2020.
   Google Scholar
• Florescu DF, Kalil AC, Hewlett AL, et al. Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease. Clin Infect Dis. 2015;61(6):969–973. doi:10.1093/cid/civ39525991468
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Nat Acad Sci. 2020;117(17):9490–9496. doi:10.1073/pnas.200416811732253318
   PubMed Web of Science ®Google Scholar
• Joyner M, Wright RS, Fairweather D, et al. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. medRxiv. 2020.
   Google Scholar
• Liu STH, Lin H-M, Baine I, et al. Convalescent plasma treatment of severe COVID-19: A matched control study. medRxiv. 2020.
   Google Scholar
• Pilz S, März W, Cashman KD, et al. Rationale and Plan for Vitamin D Food Fortification: A Review and Guidance Paper. Front Endocrinol (Lausanne). 2018;9:373. doi:10.3389/fendo.2018.0037330065699
   PubMed Web of Science ®Google Scholar
• Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi:10.1007/s00134-020-05985-932125455
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879. doi:10.1038/nm126716007097
   PubMed Web of Science ®Google Scholar
• Jalil R, Behroz MP, Mohammad A. Vitamin D3 Administration to Patients with Confirmed COVID-19. Iran J Public Health. 2020;49(Supple):1.32309218
   PubMed Web of Science ®Google Scholar
• Lin M, Gao P, Zhao T, et al. Calcitriol regulates angiotensin-converting enzyme and angiotensin converting-enzyme 2 in diabetic kidney disease. Mol Biol Rep. 2016;43(5):397–406. doi:10.1007/s11033-016-3971-526968558
   PubMed Web of Science ®Google Scholar
• Cui C, Xu P, Li G, et al. Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: role of renin-angiotensin system. Redox Biol. 2019;26:101295. doi:10.1016/j.redox.2019.10129531421410
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116. doi:10.1038/nature0371216001071
   PubMed Web of Science ®Google Scholar
• Yu L, Yuan K, Phuong HT, Park BM, Kim SH. Angiotensin-(1–5), an active mediator of renin-angiotensin system, stimulates ANP secretion via Mas receptor. Peptides. 2016;86:33–41. doi:10.1016/j.peptides.2016.09.00927660028
   PubMed Web of Science ®Google Scholar
• Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012;188(5):2127–2135. doi:10.4049/jimmunol.110241222301548
   PubMed Web of Science ®Google Scholar
• Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. 2015;7(6):4240–4270. doi:10.3390/nu706424026035247
   PubMed Web of Science ®Google Scholar
• Zdrenghea MT, Makrinioti H, Bagacean C, Bush A, Johnston SL, Stanciu LA. Vitamin D modulation of innate immune responses to respiratory viral infections. Rev Med Virol. 2017;27(1):1. doi:10.1002/rmv.1909
   Web of Science ®Google Scholar
• Arboleda JF, Fernandez GJ, Urcuqui-Inchima S. Vitamin D-mediated attenuation of miR-155 in human macrophages infected with dengue virus: implications for the cytokine response. Infect Genetics Evolution. 2019;69:12–21. doi:10.1016/j.meegid.2018.12.033
   PubMed Web of Science ®Google Scholar
• Khare D, Godbole NM, Pawar SD, et al. Calcitriol [1, 25[OH]2 D3] pre- and post-treatment suppresses inflammatory response to influenza A (H1N1) infection in human lung A549 epithelial cells. Eur J Nutr. 2013;52(4):1405–1415. doi:10.1007/s00394-012-0449-723015061
   PubMed Web of Science ®Google Scholar
• Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol. 2011;50(3):194–200. doi:10.1016/j.jcv.2010.12.00621242105
   PubMed Web of Science ®Google Scholar
• Razdan K, Singh K, Singh D. Vitamin D Levels and COVID-19 Susceptibility: is there any Correlation? Med Drug Discovery. 2020;7:100051. doi:10.1016/j.medidd.2020.100051
   PubMedGoogle Scholar
• Takeuti FAC, Guimaraes FSF, Guimaraes PSF. Applications of vitamin D in sepsis prevention. Discov Med. 2018;25(140):291–297.30021102
   PubMed Web of Science ®Google Scholar
• Sharifi A, Vahedi H, Nedjat S, Rafiei H, Hosseinzadeh-Attar MJ. Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo-controlled trial. APMIS. 2019;127(10):681–687. doi:10.1111/apm.1298231274211
   PubMed Web of Science ®Google Scholar
• Gombart AF, Pierre A, Maggini S. A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection. Nutrients. 2020;12(1):1. doi:10.3390/nu12010236
   Web of Science ®Google Scholar
• Grant WB. Variations in vitamin D production could possibly explain the seasonality of childhood respiratory infections in Hawaii. Pediatr Infect Dis J. 2008;27(9):853. doi:10.1097/INF.0b013e3181817bc1
   PubMed Web of Science ®Google Scholar
• Vásárhelyi B, Sátori A, Olajos F, Szabó A, Beko G. [Low vitamin D levels among patients at Semmelweis University: retrospective analysis during a one-year period]. Orv Hetil. 2011;152(32):1272–1277. doi:10.1556/OH.2011.2918721803724
   PubMedGoogle Scholar
• Novel, C.P.E.R.E. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua liu Xing Bing Xue Za Zhi. 2020;41(2):145–151. doi:10.3760/cma.j.issn.0254-6450.2020.02.00332064853
   PubMedGoogle Scholar
• Zhang, Y.P. Daneshkhah A, Agrawal V, Eshein A, Subramanian H, Roy HK, Backman V. The possible role of vitamin D in suppressing cytokine storm and associated mortality in COVID-19 patients. medRxiv. 2020.
   Google Scholar
• Abdelmageed MI, Abdelmoneim AH, Mustafa MI, et al. Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: an immunoinformatics approach. Biorxiv. 2020.
   Google Scholar
• Xie L, Sun C, Luo C, et al. SARS-CoV-2 and SARS-CoV spike-RBD structure and receptor binding comparison and potential implications on neutralizing antibody and vaccine development. Biorxiv. 2020.
   Google Scholar
• Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236. doi:10.1038/nrmicro209019198616
   PubMed Web of Science ®Google Scholar
• Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013;11(12):836–848. doi:10.1038/nrmicro314324217413
   PubMed Web of Science ®Google Scholar
• Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses. 2020;12(2):194. doi:10.3390/v12020194
   PubMed Web of Science ®Google Scholar
• China MoNDotPsRo. The Military Successfully Developed a Recombinant SARS-CoV-2 Vaccine. 2020.
   Google Scholar
• Trial AMVeC. 2020 Available online: https://www.modernatx.com/modernaswork-potential-vaccine-against-covid-19 (accessed on 23 March 2020).
   Google Scholar
• China coronavirus: hong Kong researchers have already developed vaccine but need time to test it, expert reveals. South China Morning Post. https://wwwscmpcom/news/hong-kong/health-environment/article/3047956/china-coronavirus-hongkong-researchers-have Accessed 282 2020 2020.
   Google Scholar
• Chen W-H, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep. 2020;1–4.
   PubMedGoogle Scholar
• Bisht H, Roberts A, Vogel L, Subbarao K, Moss B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology. 2005;334(2):160–165. doi:10.1016/j.virol.2005.01.04215780866
   PubMed Web of Science ®Google Scholar
• Okba NM, Raj VS, Haagmans BL. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. Curr Opin Virol. 2017;23:49–58. doi:10.1016/j.coviro.2017.03.00728412285
   PubMed Web of Science ®Google Scholar
• Mukherjee R. Global efforts on vaccines for COVID-19: since, sooner or later, we all will catch the coronavirus. J Biosci. 2020;45(1):1. doi:10.1007/s12038-020-00040-731965979
   PubMed Web of Science ®Google Scholar
• Australia’s been asked to make a coronavirus vaccine at ‘unprecedented speed’. Science Alert 2020 https://wwwsciencealertcom/australian-scientists-asked-to-make-coronavirusvaccine-at-unprecedented-speed Accessed 282 2020 2020.
   Google Scholar
• Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa200101731978945
   PubMed Web of Science ®Google Scholar
• Yang Z-Y, Kong W-P, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561–564. doi:10.1038/nature0246315024391
   PubMed Web of Science ®Google Scholar
• Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011;23(3):421–429. doi:10.1016/j.coi.2011.03.00821530212
   PubMed Web of Science ®Google Scholar
• Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800 Available from http://irinoviocom/news-andmedia/news/press-release-details/2020/Inovio-Accelerates-imeline-for-COVID-19-DNA-Vaccine-INO-4800/defaultaspx Accessed 033 2020 2020.
   Google Scholar
• Li J, Zhang C, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594. doi:10.3389/fimmu.2019.0059430972078
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261. doi:10.1038/nrd.2017.24329326426
   PubMed Web of Science ®Google Scholar
• Seo YB, Im SJ, Namkoong H, et al. Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity. J Virol. 2014;88(16):8998–9009. doi:10.1128/JVI.00534-1424899182
   PubMed Web of Science ®Google Scholar
• O’Neill LA, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol. 2020;20(6):335–337. doi:10.1038/s41577-020-0337-y32393823
   PubMed Web of Science ®Google Scholar
• Ventura L, Vitali M, Spica VR. BCG vaccination and socioeconomic variables vs Covid-19 global features: clearing up a controversial issue. medRxiv. 2020.
   Google Scholar
• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534. doi:10.1016/S1473-3099(20)30120-132087114
   PubMed Web of Science ®Google Scholar
• Moorlag S, Arts RJ, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25(12):1473–1478.31055165
   PubMed Web of Science ®Google Scholar
• Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med. 2018;379(2):138–149. doi:10.1056/NEJMoa171402129996082
   PubMed Web of Science ®Google Scholar
• Wardhana DE, Mandang V, Mandang V, Jim E, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011;43(3):185–190.21979284
   PubMedGoogle Scholar
• Stensballe LG, Nante E, Jensen IP, et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls: community based case–control study. Vaccine. 2005;23(10):1251–1257. doi:10.1016/j.vaccine.2004.09.00615652667
   PubMed Web of Science ®Google Scholar
• Gursel M, Gursel I. Is global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic? Med Hypotheses. 2020;109707.
   Google Scholar
• Shet A, Ray D, Malavige N, Santosham M, Bar-Zeev N. Differential COVID-19-attributable mortality and BCG vaccine use in countries. MedRxiv. 2020.
   Google Scholar
• Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. MedRxiv. 2020.
   Google Scholar
• Berg MK, Yu Q, Salvador CE, Melani I, Kitayama S. Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19. Medrxiv. 2020.
   Google Scholar
• Dayal D, Gupta S. Connecting BCG Vaccination and COVID-19: additional Data. MedRxiv. 2020.
   Google Scholar
• Klinger D, Blass I, Rappoport N, Linial M. Significantly improved COVID-19 outcomes in countries with higher BCG vaccination coverage: A multivariable analysis. medRxiv. 2020.
   Google Scholar
• Green CM, Fanucchi S, Fok ET, et al. COVID-19: A model correlating BCG vaccination to protection from mortality implicates trained immunity. MedRxiv. 2020.
   Google Scholar
• Salem A, Nofal A, Hosny D. Treatment of common and plane warts in children with topical viable bacillus Calmette‐Guerin. Pediatr Dermatol. 2013;30(1):60–63. doi:10.1111/j.1525-1470.2012.01848.x22958215
   PubMed Web of Science ®Google Scholar
• Stensballe LG, Ravn H, Birk NM, et al. BCG Vaccination at birth and rate of hospitalization for infection until 15 months of age in danish children: a randomized clinical multicenter trial. J Pediatric Infect Dis Soc. 2019;8(3):213–220. doi:10.1093/jpids/piy02929635419
   PubMed Web of Science ®Google Scholar
• de Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clin Infect Dis. 2015;60(11):1611–1619. doi:10.1093/cid/civ14425725054
   PubMed Web of Science ®Google Scholar
• Yu Y, Jin H, Chen Z, et al. Children’s vaccines do not induce cross reactivity against SARS-CoV. J Clin Pathol. 2007;60(2):208–211. doi:10.1136/jcp.2006.03889317264247
   PubMed Web of Science ®Google Scholar
• Mogica JAP, Nava V, Torres J. COVID-19 Related Mortality and The BCG Vaccine. medRxiv. 2020.
   Google Scholar
• Moorlag S, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25(12):1473–1478. doi:10.1016/j.cmi.2019.04.02031055165
   PubMed Web of Science ®Google Scholar
• Buffen K, Oosting M, Quintin J, et al. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog. 2014;10(10):e1004485. doi:10.1371/journal.ppat.100448525356988
   PubMed Web of Science ®Google Scholar